Amylin Pharmaceuticals (AMLN +18.7%) jumps after the FDA approved Bydureon, its weekly treatment...

|By:, SA News Editor

Amylin Pharmaceuticals (AMLN +18.7%) jumps after the FDA approved Bydureon, its weekly treatment for diabetes, on Friday. Alkermes (ALKS +0.8%), its partner on the drug, is also up on heavy volume.